• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新生儿和成人中 Fabry 病迟发性 GLA IVS4+919G>A 突变患者溶神经酰基鞘氨醇(lyso-Gb3)水平。

Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation.

机构信息

Department of Medical Genetics and Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.

出版信息

J Inherit Metab Dis. 2013 Sep;36(5):881-5. doi: 10.1007/s10545-012-9547-1. Epub 2012 Oct 30.

DOI:10.1007/s10545-012-9547-1
PMID:23109060
Abstract

Lyso-globotriaosylsphingosine (lyso-Gb3) is a useful biomarker in the diagnosis and monitoring of treatment for Fabry disease. However, it is unclear whether lyso-Gb3 is elevated in patients with later-onset Fabry disease. Thus, we measured lyso-Gb3 levels from dried blood spots (DBS) from male newborns with the Fabry disease later-onset phenotype, IVS4+919G>A mutation, and their family members. The lyso-Gb3 levels were below the detection limit in normal control newborns and were slightly higher in adults. In males of all ages with the IVS4+919G>A mutation, lyso-Gb3 levels were elevated and were higher than in age-matched controls. The elevation of lyso-Gb3 levels in males with the IVS4+919G>A mutation was only slightly elevated compared with patients with the classical Fabry phenotype. The measurement of lyso-Gb3 levels is useful in the diagnosis of Fabry disease, including the later-onset phenotype. The DBS lyso-Gb3 level was not elevated in IVS4+919G>A heterozygotes, and is not useful for their diagnosis. Since lyso-Gb3 levels are elevated from birth in Fabry disease males, "an elevated lyso-Gb3 level" may be of little values for deciding when to begin enzyme replacement therapy.

摘要

溶神经酰基鞘氨醇(lyso-Gb3)是诊断和监测 Fabry 病治疗的有用生物标志物。然而,尚不清楚晚发型 Fabry 病患者的 lyso-Gb3 是否升高。因此,我们测量了具有晚发型 Fabry 病表型、IVS4+919G>A 突变的男性新生儿及其家庭成员的干血斑(DBS)中的 lyso-Gb3 水平。正常对照组新生儿的 lyso-Gb3 水平低于检测限,而成年人的水平略高。在所有年龄段具有 IVS4+919G>A 突变的男性中,lyso-Gb3 水平升高,且高于年龄匹配的对照组。IVS4+919G>A 突变男性的 lyso-Gb3 水平升高与经典 Fabry 表型患者相比仅略有升高。lyso-Gb3 水平的测量对于 Fabry 病的诊断(包括晚发型表型)是有用的。IVS4+919G>A 杂合子的 DBS lyso-Gb3 水平未升高,对其诊断无帮助。由于 Fabry 病男性的 lyso-Gb3 水平从出生起就升高,“lyso-Gb3 水平升高”可能对决定何时开始酶替代治疗的价值不大。

相似文献

1
Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation.新生儿和成人中 Fabry 病迟发性 GLA IVS4+919G>A 突变患者溶神经酰基鞘氨醇(lyso-Gb3)水平。
J Inherit Metab Dis. 2013 Sep;36(5):881-5. doi: 10.1007/s10545-012-9547-1. Epub 2012 Oct 30.
2
Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A).对于携带中国热点突变(IVS4+919G>A)的晚发型法布里病患者,球三糖基鞘氨醇(溶血型Gb3)可能不是监测酶替代疗法长期治疗效果的可靠标志物。
Orphanet J Rare Dis. 2014 Jul 22;9:111. doi: 10.1186/s13023-014-0111-y.
3
Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).血浆神经酰胺三己糖苷(溶酶体神经酰胺三己糖苷)可能是中国热点晚发型突变(IVS4+919G>A)的法布雷病的生物标志物。
Clin Chim Acta. 2013 Nov 15;426:114-20. doi: 10.1016/j.cca.2013.09.008. Epub 2013 Sep 19.
4
Analysis of lyso-globotriaosylsphingosine in dried blood spots.干血斑中溶血球三糖神经酰胺的分析
Ann Lab Med. 2013 Jul;33(4):274-8. doi: 10.3343/alm.2013.33.4.274. Epub 2013 Jun 24.
5
Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.血浆溶菌酶糖脂酰基鞘氨醇作为生物标志物用于从多学科诊所选择进行基因分析的法布雷病高危患者的有效性。
Genet Med. 2019 Jan;21(1):44-52. doi: 10.1038/gim.2018.31. Epub 2018 Mar 15.
6
Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease.用于定量溶血神经酰胺三己糖苷及其类似物的纳升液相色谱-串联质谱法揭示了法布里病的一种有用生物标志物。
PLoS One. 2015 May 12;10(5):e0127048. doi: 10.1371/journal.pone.0127048. eCollection 2015.
7
Profiles of Globotriaosylsphingosine Analogs and Globotriaosylceramide Isoforms Accumulated in Body Fluids from Various Phenotypic Fabry Patients.各种表型法布雷患者体液中积累的神经酰胺糖苷脂同型物和神经酰胺糖苷脂异构体的特征。
Intern Med. 2024 Jun 1;63(11):1531-1537. doi: 10.2169/internalmedicine.2493-23. Epub 2023 Oct 20.
8
Plasma globotriaosylsphingosine as a biomarker of Fabry disease.血浆神经酰胺三己糖苷作为法布雷病的生物标志物。
Mol Genet Metab. 2010 Jul;100(3):257-61. doi: 10.1016/j.ymgme.2010.03.020. Epub 2010 Apr 1.
9
Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease.经典型和迟发型法布里病患者干血斑与血清中溶血型Gb3水平的相关性
Mol Genet Metab. 2017 Aug;121(4):320-324. doi: 10.1016/j.ymgme.2017.06.006. Epub 2017 Jun 17.
10
Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation.与迟发性心脏变异突变的法布里病患者临床表现相关的生物标志物。
Clin Chim Acta. 2017 Mar;466:185-193. doi: 10.1016/j.cca.2017.01.018. Epub 2017 Jan 18.

引用本文的文献

1
Long-read sequencing enables comprehensive molecular genetic diagnosis of Fabry disease.长读测序可实现法布瑞氏病的全面分子遗传学诊断。
Hum Genomics. 2024 Nov 28;18(1):133. doi: 10.1186/s40246-024-00697-3.
2
Evaluation, in a highly specialised enzyme laboratory, of a digital microfluidics platform for rapid assessment of lysosomal enzyme activity in dried blood spots.在一个高度专业化的酶实验室中,对用于快速评估干血斑中溶酶体酶活性的数字微流控平台进行评估。
JIMD Rep. 2024 Feb 19;65(2):124-131. doi: 10.1002/jmd2.12413. eCollection 2024 Mar.
3
2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease.

本文引用的文献

1
Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns--superiority of DNA-based to enzyme-based newborn screening for common mutations.法布里病:在台湾新生儿中常见的晚期α-半乳糖苷酶 A IVS4+919G→A 突变的发生率——基于 DNA 的新生儿筛查对常见突变的优越性优于基于酶的筛查。
Mol Med. 2012 Jul 18;18(1):780-4. doi: 10.2119/molmed.2012.00002.
2
Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.经典型法布里病患者接受酶替代治疗后血浆Globotriaosyl鞘氨醇水平升高的降低情况。
Biochim Biophys Acta. 2011 Jan;1812(1):70-6. doi: 10.1016/j.bbadis.2010.09.007. Epub 2010 Sep 17.
3
《2021年法布里病心脏表现的临床特征、诊断及临床管理TSOC专家共识》
Acta Cardiol Sin. 2021 Jul;37(4):337-354. doi: 10.6515/ACS.202107_37(4).20210601A.
4
Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease.Lyso-Gb3 与 Fabry 病患者的不良长期预后相关。
J Med Genet. 2022 Mar;59(3):287-293. doi: 10.1136/jmedgenet-2020-107338. Epub 2021 Jan 25.
5
[Impact of the inclusion of second-tier tests in the newborn screening program of Catalonia and in other international programs.].[二级检测纳入加泰罗尼亚新生儿筛查项目及其他国际项目的影响。]
Rev Esp Salud Publica. 2020 Dec 16;94:e202012158.
6
Implementation of Second-Tier Tests in Newborn Screening for Lysosomal Disorders in North Eastern Italy.意大利东北部溶酶体疾病新生儿筛查二线检测的实施
Int J Neonatal Screen. 2019 Jun 21;5(2):24. doi: 10.3390/ijns5020024. eCollection 2019 Jun.
7
Highlights on Genomics Applications for Lysosomal Storage Diseases.基因组学在溶酶体贮积症中的应用亮点
Cells. 2020 Aug 14;9(8):1902. doi: 10.3390/cells9081902.
8
Galectin-3 and β-trace protein concentrations are higher in clinically unaffected patients with Fabry disease.半乳糖凝集素-3 和β-痕迹蛋白在无临床表现的法布瑞氏病患者中浓度更高。
Sci Rep. 2019 Apr 17;9(1):6235. doi: 10.1038/s41598-019-42727-4.
9
Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.从阿加糖酶α转换为阿加糖酶β作为法布里病的酶替代疗法后血浆葡萄糖神经酰胺水平的降低。
JIMD Rep. 2016;25:95-106. doi: 10.1007/8904_2015_483. Epub 2015 Aug 25.
10
Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A).对于携带中国热点突变(IVS4+919G>A)的晚发型法布里病患者,球三糖基鞘氨醇(溶血型Gb3)可能不是监测酶替代疗法长期治疗效果的可靠标志物。
Orphanet J Rare Dis. 2014 Jul 22;9:111. doi: 10.1186/s13023-014-0111-y.
Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G→A).
中国热点晚发性 Fabry 突变(IVS4+919G→A)受试者的酶测定和临床评估。
J Inherit Metab Dis. 2010 Oct;33(5):619-24. doi: 10.1007/s10545-010-9166-7. Epub 2010 Sep 7.
4
How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?尿溶菌酶糖蛋白 3 作为法布里病生物标志物的功能如何?
Clin Chim Acta. 2010 Dec 14;411(23-24):1906-14. doi: 10.1016/j.cca.2010.07.038. Epub 2010 Aug 14.
5
Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.组织和血浆神经酰胺三己糖苷脂可以作为评估法布雷病酶替代治疗的生物标志物。
Biochem Biophys Res Commun. 2010 Sep 3;399(4):716-20. doi: 10.1016/j.bbrc.2010.08.006. Epub 2010 Aug 6.
6
Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease.血浆球三糖基鞘氨醇:法布里病的诊断价值及其与临床表现的关系
Biochim Biophys Acta. 2010 Sep;1802(9):741-8. doi: 10.1016/j.bbadis.2010.05.003. Epub 2010 May 13.
7
Plasma globotriaosylsphingosine as a biomarker of Fabry disease.血浆神经酰胺三己糖苷作为法布雷病的生物标志物。
Mol Genet Metab. 2010 Jul;100(3):257-61. doi: 10.1016/j.ymgme.2010.03.020. Epub 2010 Apr 1.
8
High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population.台湾华裔人群新生儿筛查显示法布里病心脏变异型的高发病率。
Circ Cardiovasc Genet. 2009 Oct;2(5):450-6. doi: 10.1161/CIRCGENETICS.109.862920. Epub 2009 Jul 24.
9
Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).台湾地区对法布里病进行的新生儿筛查显示,迟发型GLA突变c.936+919G>A(IVS4+919G>A)的发病率很高。
Hum Mutat. 2009 Oct;30(10):1397-405. doi: 10.1002/humu.21074.
10
Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study.心脏法布里病患者的终末期心脏表现:一项心电图、超声心动图及尸检研究
J Cardiol. 2008 Feb;51(1):50-9. doi: 10.1016/j.jjcc.2007.12.001. Epub 2008 Feb 6.